{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:00:51Z","timestamp":1791090051849,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.molmed.2007.06.001","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T13:03:26Z","timestamp":1183035806000},"page":"298-309","source":"Crossref","is-referenced-by-count":184,"title":["Targeting farnesoid X receptor for liver and metabolic disorders"],"prefix":"10.1016","volume":"13","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annibale","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2007.06.001_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-1119(02)00557-7","article-title":"Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters","volume":"290","author":"Huber","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.molmed.2007.06.001_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/MCB.23.3.864-872.2003","article-title":"Identification of farnesoid X receptor \u03b2 as a novel mammalian nuclear receptor sensing lanosterol","volume":"23","author":"Otte","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2007.06.001_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.06.001_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.06.001_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib8","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib9","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib12","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1021\/jm0582221","article-title":"Farnesoid X Receptor: from structure to potential clinical applications","volume":"48","author":"Pellicciari","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/mol.105.012104","article-title":"The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)\/9-cis retinoid X receptor and regulates transcription of FXR responsive genes","volume":"68","author":"Rizzo","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.molmed.2007.06.001_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.molmed.2007.06.001_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/mp060010s","article-title":"Role of Nuclear receptors in the adaptive response to bille acids and cholestasis: pathogenetic and therapeutic considerations","volume":"3","author":"Zollner","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molmed.2007.06.001_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1073\/pnas.0237082100","article-title":"Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor","volume":"100","author":"Goodwin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.06.001_bib17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.06.001_bib18","doi-asserted-by":"crossref","first-page":"45062","DOI":"10.1074\/jbc.M307145200","article-title":"Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity","volume":"278","author":"Guo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-2275(20)30180-2","article-title":"BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis","volume":"43","author":"Edwards","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2007.06.001_bib20","doi-asserted-by":"crossref","first-page":"49517","DOI":"10.1074\/jbc.M409041200","article-title":"The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity","volume":"279","author":"Zhang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib21","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G-protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2007.06.001_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-2006-933560","article-title":"Primary sclerosing cholangitis: epidemiology, natural history, and prognosis","volume":"26","author":"Levy","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.molmed.2007.06.001_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.1840400434","article-title":"Primary biliary cirrhosis: report of a focus study group","volume":"40","author":"Bergasa","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-2275(20)31482-6","article-title":"Regulation of cholesterol-7\u03b1-hydroxylase: BAREly missing a SHP","volume":"43","author":"Davis","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2007.06.001_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-1119(00)00518-7","article-title":"Regulation of cholesterol 7\u03b1-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXR\u03b1)","volume":"262","author":"Chiang","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.molmed.2007.06.001_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","article-title":"LXRS and FXR: the yin and yang of cholesterol and fat metabolism","volume":"68","author":"Kalaany","year":"2006","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.molmed.2007.06.001_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib30","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1210\/me.2001-0194","article-title":"The small heterodimer partner interacts with the liver X receptor \u03b1 and represses its transcriptional activity","volume":"16","author":"Brendel","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2007.06.001_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1534-5807(02)00154-5","article-title":"Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis","volume":"2","author":"Kerr","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1534-5807(02)00187-9","article-title":"Redundant pathways for negative feedback regulation of bile acid production","volume":"2","author":"Wang","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.molmed.2007.06.001_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, Shp, mediates bile acid-induced inhibition of the rat bile acid transporter Ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2007.06.001_bib34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/gast.2001.21176","article-title":"Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver","volume":"120","author":"Kullak-Ublick","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2007.06.001_bib35","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1074\/jbc.M011610200","article-title":"Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor","volume":"276","author":"Ananthanarayanan","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1081\/DMR-120026398","article-title":"Regulation of drug and bile salt transporters in liver and intestine","volume":"35","author":"Kullak-Ublick","year":"2003","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.molmed.2007.06.001_bib37","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M109326200","article-title":"Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor","volume":"277","author":"Kast","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib38","doi-asserted-by":"crossref","first-page":"51085","DOI":"10.1074\/jbc.M308321200","article-title":"Farnesoid X receptor activates transcription of the phospholipid pump MDR3","volume":"278","author":"Huang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib39","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.20961","article-title":"OST\u03b1\u2013OST\u03b2: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia","volume":"42","author":"Ballatori","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib40","doi-asserted-by":"crossref","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","article-title":"Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer","volume":"274","author":"Grober","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib41","doi-asserted-by":"crossref","first-page":"27703","DOI":"10.1074\/jbc.M302128200","article-title":"Farnesoid X receptor regulates bile acid\u2013amino acid conjugation","volume":"278","author":"Pircher","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib42","doi-asserted-by":"crossref","first-page":"42549","DOI":"10.1074\/jbc.M107557200","article-title":"Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor","volume":"276","author":"Song","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib43","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0016-5085(03)00388-3","article-title":"FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity","volume":"124","author":"Barbier","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2007.06.001_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-200410000-00001","article-title":"Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene","volume":"14","author":"Gnerre","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.molmed.2007.06.001_bib45","doi-asserted-by":"crossref","first-page":"19081","DOI":"10.1074\/jbc.M600116200","article-title":"Pregnane x receptor is a target of farnesoid x receptor","volume":"281","author":"Jung","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib46","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2007.06.001_bib47","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1073\/pnas.212494599","article-title":"Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR)","volume":"99","author":"Sonoda","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.06.001_bib48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2007.06.001_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/bmj.3.5879.520","article-title":"Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy","volume":"3","author":"Bell","year":"1973","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2007.06.001_bib51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(74)91134-9","article-title":"Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia","volume":"2","author":"Miller","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2007.06.001_bib52","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2007.06.001_bib53","doi-asserted-by":"crossref","first-page":"45685","DOI":"10.1074\/jbc.M404255200","article-title":"Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4","volume":"279","author":"Hirokane","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib54","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1210\/me.15.10.1720","article-title":"Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids","volume":"15","author":"Kast","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2007.06.001_bib55","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2007.06.001_bib56","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1074\/jbc.M209525200","article-title":"The farnesoid X-receptor is an essential regulator of cholesterol homeostasis","volume":"278","author":"Lambert","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1101\/gad.1138104","article-title":"Peroxisome proliferator-activated receptor-\u03b3 coactivator 1\u03b1 (PGC-1\u03b1) regulates triglyceride metabolism by activation of the nuclear receptor FXR","volume":"18","author":"Zhang","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.molmed.2007.06.001_bib58","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/mol.106.023820","article-title":"The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo","volume":"70","author":"Rizzo","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.molmed.2007.06.001_bib59","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib60","doi-asserted-by":"crossref","first-page":"20420","DOI":"10.1074\/jbc.M302505200","article-title":"Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor","volume":"278","author":"Anisfeld","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib61","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1210\/en.2004-0965","article-title":"Regulation of carbohydrate metabolism by the farnesoid x receptor","volume":"146","author":"Stayrook","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2007.06.001_bib62","doi-asserted-by":"crossref","first-page":"23158","DOI":"10.1074\/jbc.M314322200","article-title":"Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1","volume":"279","author":"Yamagata","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib63","doi-asserted-by":"crossref","first-page":"29971","DOI":"10.1074\/jbc.M501931200","article-title":"The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition","volume":"280","author":"Duran-Sandoval","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/diabetes.53.4.890","article-title":"Glucose regulates the expression of the farnesoid X receptor in liver","volume":"53","author":"Duran-Sandoval","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2007.06.001_bib65","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.06.001_bib66","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2007.06.001_bib67","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2007.06.001_bib68","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2007.06.001_bib69","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","article-title":"Benefit of farnesoid X receptor inhibition in obstructive cholestasis","volume":"103","author":"Stedman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.06.001_bib70","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1194\/jlr.M500427-JLR200","article-title":"Fxr(\u2212\/\u2212) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids","volume":"47","author":"Marschall","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2007.06.001_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/jpet.300.1.97","article-title":"Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats","volume":"300","author":"Cherrington","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2007.06.001_bib72","doi-asserted-by":"crossref","first-page":"22250","DOI":"10.1074\/jbc.M314111200","article-title":"Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice","volume":"279","author":"Assem","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2007.06.001_bib73","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","article-title":"CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice","volume":"42","author":"Wagner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib74","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1073\/pnas.0630614100","article-title":"Induction of bilirubin clearance by the constitutive androstane receptor (CAR)","volume":"100","author":"Huang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.molmed.2007.06.001_bib75","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","article-title":"Liver fibrosis \u2013 from bench to bedside","volume":"38","author":"Friedman","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2007.06.001_bib76","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2007.06.001_bib77","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2007.06.001_bib78","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor \u03b3 contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2007.06.001_bib79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1042\/BST0341119","article-title":"The impact of pregnane X receptor activation on liver fibrosis","volume":"34","author":"Wright","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2007.06.001_bib80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","article-title":"Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells","volume":"119","author":"Marra","year":"2000","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.molmed.2007.06.001_bib81","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00000441-200512000-00011","article-title":"Nonalcoholic steatohepatitis and the metabolic syndrome","volume":"330","author":"Neuschwander-Tetri","year":"2005","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.molmed.2007.06.001_bib83","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/jhep.2003.50420","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib84","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2007.06.001_bib85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1121435","article-title":"Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration","volume":"312","author":"Huang","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.06.001_bib86","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm1138","article-title":"Prevention of cholesterol gallstone disease by FXR agonists in a mouse model","volume":"10","author":"Moschetta","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2007.06.001_bib87","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","article-title":"Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"46","author":"Hanniman","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2007.06.001_bib88","doi-asserted-by":"crossref","first-page":"E716","DOI":"10.1152\/ajpendo.00355.2005","article-title":"Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters","volume":"290","author":"Bilz","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2007.06.001_bib89","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2007.06.001_bib90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2007.06.001_bib91","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","article-title":"Bile acid-induced negative feedback regulation of the human ileal bile acid transporter","volume":"40","author":"Neimark","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2007.06.001_bib92","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/B:REMD.0000045103.00467.9a","article-title":"The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism","volume":"5","author":"Claudel","year":"2004","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.molmed.2007.06.001_bib93","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for the FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molmed.2007.06.001_bib94","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/mol.104.007054","article-title":"The hypolipidemic natural product guggulsterone Is a promiscuous steroid receptor ligand","volume":"67","author":"Burris","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.molmed.2007.06.001_bib95","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.290.6.765","article-title":"Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial","volume":"290","author":"Szapary","year":"2003","journal-title":"J. Am. Med. Assoc."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491407001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491407001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T05:58:23Z","timestamp":1629093503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491407001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1471491407001062"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2007.06.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}